Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 10, 2019 - Issue
Submit an article Journal homepage
91
Views
1
CrossRef citations to date
0
Altmetric
Case Report

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations

Madhu M Ouseph1 Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI02903, USA
,
Angela Taber2 Division of Medical Oncology, Miriam Hospital and Alpert Medical School at Brown University, Providence, RI02906, USA
,
Humera Khurshid3 Division of Medical Oncology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI02903, USA
,
Russell Madison4 Foundation Medicine, Inc ., Cambridge, MA02141, USA
,
Bassam I Aswad1 Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI02903, USA
,
Murray B Resnick1 Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI02903, USA
,
Evgeny Yakirevich1 Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI02903, USA
,
Siraj M Ali4 Foundation Medicine, Inc ., Cambridge, MA02141, USA
&
Nimesh R Patel1 Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI02903, USACorrespondence[email protected]
 show all
Pages 81-86 | Published online: 15 Aug 2019

References

  • Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703.20979469
  • Asao T, Takahashi F, Takahashi K. Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respir Investig. 2019;57(1):20–26.
  • van der Wekken AJ, Saber A, Hiltermann TJ, Kok K, van den Berg A, Groen HJ. Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. Crit Rev Oncol Hematol. 2016;100:107–116. doi:10.1016/j.critrevonc.2016.01.02426852079
  • Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472–1482. doi:10.1158/1078-0432.CCR-11-290622235099
  • Cheng H, Zou Y, Ross JS, et al. RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 Inhibitors. Cancer Discov. 2015;5(12):1262–1270. doi:10.1158/2159-8290.CD-14-097126370156
  • Tuononen K, Kero M, Maki-Nevala S, et al. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients. Genes Chromosomes Cancer. 2014;53(11):895–901. doi:10.1002/gcc.2219824942490
  • Gao C, Wang Y, Broaddus R, Sun L, Xue F, Zhang W. Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget. 2018;9(4):5492–5508. doi:10.18632/oncotarget.2369529435196
  • Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci. 2016;73(6):1209–1224. doi:10.1007/s00018-015-2117-626755435
  • Jeong WJ, Ro EJ, Choi KY. Interaction between Wnt/beta-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of beta-catenin and RAS by targeting the Wnt/beta-catenin pathway. NPJ Precis Oncol. 2018;2(1):5. doi:10.1038/s41698-018-0049-y29872723
  • Fang D, Hawke D, Zheng Y, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007;282(15):11221–11229. doi:10.1074/jbc.M61187120017287208
  • Yamaguchi H, Hsu JL, Hung MC. Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Front Oncol. 2012;2:15. doi:10.3389/fonc.2012.0001522649777
  • Pai SG, Carneiro BA, Mota JM, et al. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10(1):101. doi:10.1186/s13045-017-0471-628476164
  • Zhang Q, Xiao M, Gu S, et al. ALK phosphorylates SMAD4 on tyrosine to disable TGF-beta tumour suppressor functions. Nat Cell Biol. 2019;21(2):179–189. doi:10.1038/s41556-018-0264-330664791

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.